Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer's disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector's strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/31/13 | undisclosed | Series A |
OrbiMed Advisors Polaris Partners | undisclosed |
| 09/16/15 | $32,000,000 | Series C |
Mission Bay Capital OrbiMed Advisors Polaris Partners Topspin Fund | undisclosed |
| 01/07/16 | $29,500,000 | Series D |
AbbVie Biotech Ventures Amgen Business Development Dementia Discovery Fund Merck Research Labs Venture Fund Mission Bay Capital OrbiMed Advisors Polaris Partners Topspin Partners | undisclosed |
